Related Experiment Videos
Raf-1 expression may influence progression to androgen insensitive prostate cancer
R Mukherjee1, J M S Bartlett, N S Krishna
1Endocrine Cancer Group, Division of Cancer Studies and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom.
The Prostate
|January 25, 2005
Summary
Increased Raf-1 expression in prostate cancer correlates with faster relapse. The HER2/Raf-1/AP-1 pathway may drive androgen-insensitive prostate cancer (AIPC) and offers potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The MAP kinase pathway is implicated in the development of androgen-insensitive prostate cancer (AIPC).
- Previous research identified gene amplification in this pathway during AIPC progression.
Purpose of the Study:
- To investigate the role of Raf-1 protein expression in the development and progression of AIPC.
- To correlate Raf-1 expression with other pathway members and clinical outcomes.
Main Methods:
- Immunohistochemistry (IHC) was used to analyze Raf-1 protein expression.
- 65 paired tumor specimens before and after AIPC development were examined.
- Expression levels were correlated with other pathway members and time to relapse.
Main Results:
- Elevated Raf-1 expression in AIPC was associated with a significantly shorter median time to biochemical relapse (1.16 years vs. 2.62 years).
- In AIPC tumors, Raf-1 expression significantly correlated with HER2 and c-fos expression.
- These findings suggest a link between the HER2/Raf-1/AP-1 axis and AIPC.
Conclusions:
- The HER2/Raf-1/AP-1 axis may drive AIPC development and contribute to early relapse.
- Targeting components of this pathway could represent novel therapeutic strategies for AIPC patients.